Citations

Mayo Clinic

Clear

511 citation(s) found for "Murad, M H".

Adrenal infections update: how radiologists can contribute to patient care
Abreu‐Gomez, Jorge , Ezzat, Shereen , Navin, Patrick J. , Westphalen, Antonio C. , Ezzat, Shereen , Navin, Patrick , Murad, Vanessa , Westphalen, Antonio Carlos

British Journal of Radiology | February 11, 2025 | Volume: 98 | Issue: 1168 | Pages: 496-508

10.1093/bjr/tqaf025 | PMID 39932870 Get It

Abstract Adrenal infections are considered clinically important but often go unrecognized, with a significant number of cases only diagnosed post-mortem. The limited evidence regarding imaging findings in the literature emphasizes the need to detect and diagnose these infections early in disease course to improve patient outcomes. A range of microorganisms, including fungi, viruses, parasites, and bacteria, can directly or indirectly affect the morphology and function of the adrenal glands. When evaluating a patient with adrenal infection, several immunological and hormonal factors should be considered, such as the status of the hypothalamic-pituitary-adreno cortical axis and the serum cortisol level. Moreover, certain microorganisms specifically target one of the zones of the adrenal glands or vascular supply, resulting in distinct imaging manifestations. The purpose of this article is to describe the fundamental clinical features and imaging manifestations associated with adrenal infections, enabling radiologists to make informed interpretations and contribute to accurate diagnostic assessments.
Sickle cell trait does not cause “sickle cell crisis” leading to exertion-related death: a systematic review
Weeks, Lachelle D. , Wilson, Allecia M. , Naik, Rakhi P. , Efebera, Yvonne A. , Mahajan, Anjlee , McGann, Patrick T. , Verhovsek, Madeleine , Zaidi, Ahmar U. , Donald, Chancellor E. , Mitchell, Roger A., McGann, Patrick T , Verhovsek, Madeleine , Zaidi, Ahmar U , DeBaun, Michael R , Donald, Chancellor , Weeks, Lachelle Dawn , Murad, M. Hassan , Weyand, Angela C. , DeBaun, Michael R.

Blood | January 30, 2025 | Volume: 145 | Issue: 13 | Pages: 1345-1352

10.1182/blood.2024026899 | PMID 39882975 Get It

Abstract Globally, an estimated 300 million individuals have sickle cell trait (SCT), the carrier state for sickle cell disease (SCD). Although SCD is associated with increased morbidity and shortened life span, SCT has a life span comparable with that of the general population. However, “sickle cell crisis” has been used as a cause of death for decedents with SCT in reports of exertion-related death in athletes, military personnel, and individuals in police custody. To appraise this practice, the American Society of Hematology convened an expert panel of hematologists and forensic pathologists to conduct a systematic review of the literature relating to the occurrence of sickle cell pain crises and exertion-related mortality in people with SCT. Multiple bibliographic databases were searched with controlled vocabulary and keywords related to “sickle cell trait,” “vaso-occlusive pain,” and “death,” yielding 18 of 1474 citations. Independent pairs of reviewers selected studies and extracted data. We found no studies comparing uncomplicated acute pain crises in individuals with SCT and SCD. Additionally, no study was identified to support the occurrence of acute vaso-occlusive pain crises in individuals with SCT. Furthermore, this systematic review did not identify any evidence to support an association between SCT and sudden unexplained death in the absence of exertion-related rhabdomyolysis. We conclude that there are no data to support the diagnosis of acute vaso-occlusive sickle cell crisis as a cause of death in SCT, nor does the available evidence support the use of SCT as a cause of exertion-related death without rhabdomyolysis.
Incorporating uncertainty in the baseline risk: An R Shiny tool and an empirical study
Murad, M. Hassan , Murad, M Hassan , Lin, Lifeng

Cochrane Evidence Synthesis and Methods | January 29, 2025 | Volume: 3 | Issue: 2 | Pages: No page available

10.1002/cesm.70018 | PMID 40475917 Get It

Abstract The common practice in meta‐analysis and clinical practice guidelines is to derive the absolute treatment effect (also called risk difference, RD) from a combination of a pooled relative risk (RR) that resulted from a meta‐analysis, and a user‐provided baseline risk (BR). However, this method does not address the uncertainty in BR. We developed a web‐based R Shiny tool to perform simple microsimulation and incorporate uncertainty in BR into the precision of RD. We empirically evaluated this approach by estimating the impact of incorporating this uncertainty when BR is derived from the control group rates in 3,128 meta‐analyses curated from the Cochrane Library (26,964 individual studies). When BR was derived from the largest study in each meta‐analysis, the median width of the CI of BR was 11.6% (interquartile range (IQR), 6.30%–18.5%). Incorporating this uncertainty in BR led to expansion of the RD CI by a median of 8 per 1,000 persons (IQR 2–24). This expansion increased in a linear fashion with BR imprecision and was more prominent in meta‐analyses with low BR. This study provides a web‐based tool to perform simple microsimulation and incorporate uncertainty in BR into the CI of RD.
Visual Explanation of the Assessment of Certainty of Evidence for Systematic Review and Meta-analysis
Naqvi, Syed Arsalan Ahmed , Faisal, Kunwer Sufyan , Imran, Manal , Khan, Muhammad Ali , Khakwani, Kaneez Zahra Rubab, He, Huan, Murad, M. Hassan , Riaz, Irbaz Bin

2024 Workshop on Visual Analytics in Healthcare (VAHC) | January 17, 2025 | Volume: No volume available | Issue: No issue available | Pages: 10-14

10.1109/vahc65315.2024.00010 Get It

Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology
Blitzblau, Rachel , Aasi, Sumaira Z. , Alam, Murad, Amini, Arya , Bibee, Kristin , Bolotin, Diana, DiMaio, Dominick J. , Farma, Jeffrey M. , Ghosh, Karthik, Harms, Kelly L. , LeBoeuf, Nicole R. , Lukens, John N. , Manber, Susan, Mark, Lawrence A. , Medina, Theresa , Nehal, Kishwer S. , Paragh, György , Patel, Tejesh , Rich, Jason T. , Shaha, Ashok R. , Sharma, Bhavina, Sokumbi, Yemi, Thomas, Valencia D., Tomblinson, Courtney M. , Venkat, Puja , Xu, Yaohui , Yu, Siegrid S., McCullough, Beth, Espinosa, Sara, Bordeaux, Jeremy S. , Chen, Pei-Ling , Contreras, Carlo M. , Donigan, Jessica M. , Medina, Theresa Michelle , Nghiem, Paul , Olino, Kelly L. , Park, Soohyung , Sharma, Bhavina, Srivastava, Divya , Yusuf, Mehran Behruj

Journal of the National Comprehensive Cancer Network | January 15, 2025 | Volume: 23 | Issue: 1 | Pages: No page available

10.6004/jnccn.2025.0001 | PMID 39819674 Get It

Dermatofibrosarcoma protuberans (DFSP) is a rare cutaneous soft tissue sarcoma and affects an estimated 1,500 people annually in the United States. DFSP frequently exhibits extensive local infiltration. Initial treatment is through surgical excision, and care should be taken to ensure that negative margins are achieved to minimize recurrence. Although DFSP has a reported high rate of recurrence, metastasis is more uncommon. Fibrosarcomatous DFSP is an aggressive variant with an increased risk for local recurrence and metastasis. If achieving negative margins or resection is not feasible, radiation therapy or systemic treatment are options that may be considered by a multidisciplinary team. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) outline recommended treatment options available for DFSP.
Collaborative large language models for automated data extraction in living systematic reviews
Ayub, Umair , Naqvi, Syed Arsalan Ahmed , Khakwani, Kaneez Zahra Rubab, Sipra, Zaryab bin Riaz, Raina, Ammad, Zhou, Sihan , Saeidi, Amir, Zou, Jia , Leventakos, Konstantinos , Kehl, Kenneth L. , Palmer, Jeanne , Baral, Chitta , He, Huan , Hasan, Bashar , Murad, Mohammad Hassan, Riaz, Irbaz Bin , Khan, Muhammad Ali , He, Huan , Saeidi, Amir, Hasan, Bashar , Rumble, R. Bryan , Bitterman, Danielle S. , Warner, Jeremy L. , Tevaarwerk, Amyé , Murad, M. Hassan

Journal of the American Medical Informatics Association | January 3, 2025 | Volume: 32 | Issue: 4 | Pages: 638-647

10.1093/jamia/ocae325 | PMID 39836495 Get It

Abstract Objective Data extraction from the published literature is the most laborious step in conducting living systematic reviews (LSRs). We aim to build a generalizable, automated data extraction workflow leveraging large language models (LLMs) that mimics the real-world 2-reviewer process. Materials and Methods A dataset of 10 trials (22 publications) from a published LSR was used, focusing on 23 variables related to trial, population, and outcomes data. The dataset was split into prompt development (n = 5) and held-out test sets (n = 17). GPT-4-turbo and Claude-3-Opus were used for data extraction. Responses from the 2 LLMs were considered concordant if they were the same for a given variable. The discordant responses from each LLM were provided to the other LLM for cross-critique. Accuracy, ie, the total number of correct responses divided by the total number of responses, was computed to assess performance. Results In the prompt development set, 110 (96%) responses were concordant, achieving an accuracy of 0.99 against the gold standard. In the test set, 342 (87%) responses were concordant. The accuracy of the concordant responses was 0.94. The accuracy of the discordant responses was 0.41 for GPT-4-turbo and 0.50 for Claude-3-Opus. Of the 49 discordant responses, 25 (51%) became concordant after cross-critique, increasing accuracy to 0.76. Discussion Concordant responses by the LLMs are likely to be accurate. In instances of discordant responses, cross-critique can further increase the accuracy. Conclusion Large language models, when simulated in a collaborative, 2-reviewer workflow, can extract data with reasonable performance, enabling truly “living” systematic reviews.
The Clinical Impact of Mitral Gradient Post Transcatheter Edge‐To‐Edge Repair: A Systematic Review and Meta‐Analysis
Almiro, Alyaman , Khan, Jibran , Gerberi, Dana , Thaden, Jeremy J. , Rihal, Charanjit S. , Eleid, Mackram F. , Alabdaljabar, Mohamad S. , Almiro, Alyaman , Gerberi, Dana J., Eleid, Mackram F , Murad, M. Hassan , Rihal, Charanjit S.

Catheterization and Cardiovascular Interventions | December 6, 2024 | Volume: 105 | Issue: 2 | Pages: 413-425

10.1002/ccd.31321 | PMID 39639557 Get It

ABSTRACTBackgroundMitral transcatheter edge‐to‐edge repair (TEER) is a minimally invasive therapy for severe mitral regurgitation (MR) in patients with high surgical risk. TEER results in a tissue bridge that decreases mitral valve area, potentially leading to elevated mean gradient. The clinical impact of elevated gradient on outcomes is unclear.MethodsThis systematic review and meta‐analysis was based on a comprehensive search of five databases. We included studies that evaluated post mitral TEER gradient on one of the following outcomes: all‐cause mortality, combined endpoints, symptoms, hospitalizations, and mitral valve re‐intervention. Meta‐analysis was conducted using the random‐effects model.ResultsOut of 6458 citations, 17 studies were included (2017−2024) reporting on 7748 patients. There was significant heterogeneity between studies related to the cutoff used to define elevated gradient, etiology of MR, and outcomes. Elevated mitral gradient post TEER (4, 4.5, 5 mmHg) was associated with worse combined endpoint (HR = 1.35, 95% CI 1.07−1.71; I2 64%), but not all‐cause mortality (HR = 1.25, 95% CI 0.97−1.59; I2 45%) or risk of hospitalization. For the combined endpoint, this association was mainly significant in patients who had mitral gradient assessed using discharge echocardiogram (HR = 1.39, 95% CI 1.07−1.81; I2 62%) for all patients and for those with degenerative MR.ConclusionDespite the heterogeneity between studies, the current analysis suggests that patients with elevated mitral gradient post TEER are at risk of worse clinical outcomes, particularly in patients who had mitral gradient assessed using discharge transthoracic echocardiogram.
What Is the Accuracy of 16S PCR Followed by Sanger Sequencing or Next-generation Sequencing in Native Vertebral Osteomyelitis? A Systematic Review and Meta-analysis
Mahmoud, Omar , Petri, Francesco , Zein, Said El , Verdoorn, Jared T. , Berbari, Elie F. , Mahmoud, Omar K , El Zein, Said , Verdoorn, Jared T , Petri, Francesco , Fida, Madiha , Diehn, Felix E. , Schuetz, Audrey N. , Murad, M. Hassan , Nassr, Ahmad

Clinical Orthopaedics & Related Research | December 5, 2024 | Volume: 483 | Issue: 5 | Pages: 930-938

10.1097/corr.0000000000003314 | PMID 39637246 Get It

Background Identifying a microorganism in patients with native vertebral osteomyelitis presents diagnostic challenges. Microorganism identification through culture-based methods is constrained by prolonged processing times and sensitivity limitations. Despite the availability of molecular diagnostic techniques for identifying microorganisms in native vertebral osteomyelitis, there is considerable variability in reported sensitivity and specificity across studies, leading to uncertainty in their clinical utility. Questions/purposes What are the sensitivity, specificity, and diagnostic odds ratios for 16S broad-range PCR followed by Sanger sequencing (16S) and metagenomic next-generation sequencing (NGS) for detecting bacteria in native vertebral osteomyelitis? Methods On June 29, 2023, we searched Cochrane, Embase, Medline, and Scopus for results from January 1970 to June 2023. Included studies involved adult patients with suspected native vertebral osteomyelitis undergoing molecular diagnostics—16S bacterial broad-range PCR followed by Sanger sequencing and shotgun or targeted metagenomic NGS—for bacteria detection. Studies involving nonnative vertebral osteomyelitis and cases of brucellar, tubercular, or fungal etiology were excluded. The reference standard for the diagnosis of native vertebral osteomyelitis was a composite clinical- and investigator-defined native vertebral osteomyelitis diagnosis. Diagnostic performance was assessed using a bivariate random-effects model. Risk of bias and diagnostic applicability were evaluated using the revised Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. After a manual screening of 3403 studies, 10 studies (5 on 16S, 5 on NGS) were included in the present analysis, from which 391 patients were included from a total of 958 patients overall. Quality assessment via QUADAS-2 criteria showed moderate risk of bias and good applicability. Results 16S showed 78% (95% confidence interval [CI] 95% CI 31% to 96%) sensitivity and 94% (95% CI 73% to 99%) specificity, whereas NGS demonstrated 82% (95% CI 63% to 93%) sensitivity and 71% (95% CI 37% to 91%) specificity. In addition, the diagnostic ORs were 59 (95% CI 9 to 388) and 11 (95% CI 4 to 35) for 16S and NGS, respectively. Summary receiver operating characteristic curves showed high test performance for 16S (area under the curve for 16S 95% [95% CI 93% to 97%] and for NGS 89% [95% CI 86% to 92%]). Certainty in estimates was moderate because of sample size limitations. Conclusion This meta-analysis found moderate-to-high diagnostic performance of molecular methods on direct patient specimens for the diagnosis of native vertebral osteomyelitis. When used as a complementary test to microbiological analyses, a positive 16S result rules in the diagnosis of native vertebral osteomyelitis, while further studies are needed to understand the role of NGS in the diagnosis of native vertebral osteomyelitis. When available, these tests should be used in addition to conventional microbiology, especially in complex cases with extensively negative standard microbiological test results, to detect fastidious bacteria or to confirm the causative bacteria when their isolation and pathogenicity are unclear. A large sample size is needed in future research to understand the use of these techniques as standalone tests for diagnosis. Level of Evidence Level III, diagnostic study.
Mitochondrial metabolism and epigenetic crosstalk drive the SASP
Martini, Hélène , Birch, Jodie , Victorelli, Stella , Lagnado, Anthony B. , Pirius, Nicholas, Han, Yeaeun , Havas, Aaron , Jurk, Diana , Adams, Peter D. , Passos, João F. , Victorelli, Stella , Lagnado, Anthony , Franco, Ana, Lee, Gung, Han, Yeaeun , Rowsey, Jennifer, Gaspar-Maia, Alexandre , Havas, Aaron , Porritt, Rebecca , Maddocks, Oliver , Jurk, Diana , Khosla, Sundeep , Adams, Peter , Passos, João F , Marques, Francisco Madeira , Franco, Ana Catarina , Lee, Gung , Rowsey, Jennifer L. , Ismail, Wazim Mohammed , Mazzone, Amelia , Espe, Tianna, Hitosugi, Taro , Li, Ya , Washington, Alexander M. , Murad, Rabi , Lei, Xue , Espíndola‐Netto, Jair Machado , Saul, Dominik , Khosla, Sundeep , Kostallari, Enis , Gaspar‐Maia, Alexandre

No container title available | December 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5278203/v1 | PMID 39678326 Get It

Abstract Senescent cells drive tissue dysfunction through the senescence-associated secretory phenotype (SASP). We uncovered a central role for mitochondria in the epigenetic regulation of the SASP, where mitochondrial-derived metabolites, specifically citrate and acetyl-CoA, fuel histone acetylation at SASP gene loci, promoting their expression. We identified the mitochondrial citrate carrier (SLC25A1) and ATP-citrate lyase (ACLY) as critical for this process. Inhibiting these pathways selectively suppresses SASP without affecting cell cycle arrest, highlighting their potential as therapeutic targets for age-related inflammation. Notably, SLC25A1 inhibition reduces systemic inflammation and extends healthspan in aged mice, establishing mitochondrial metabolism as pivotal to the epigenetic control of aging.
Association between antiphospholipid antibodies and diffuse alveolar haemorrhage risk in systemic lupus erythematosus: a systematic review and meta-analysis
González‐Treviño, Mariana , Figueroa‐Parra, Gabriel , Yang, Jeffrey X. , Prokop, Larry J. , Gamal, Sherif M. , Narváez, Javier , Yang, Xuwei , Narvaez, Javier , Quintana, Rosana M , Specks, Ulrich , Yang, Xuwei , Duarte-García, Alí , Figueroa-Parra, Gabriel , Prokop, Larry , Gonzalez-Treviño, Mariana , García, Mercedes , James, Judith A. , Knight, Jason S , Murad, M. Hassan , Pons‐Estel, Bernardo Antonio , Specks, Ulrich , Duarte‐García, Alí

Rheumatology | November 19, 2024 | Volume: 64 | Issue: 4 | Pages: 1598-1608

10.1093/rheumatology/keae632 | PMID 39558618 Get It

Abstract Objective To assess the association of aPL and diffuse alveolar haemorrhage (DAH) in patients with SLE by performing a systematic review and meta-analysis. Methods Multiple databases were systematically searched from inception to February 2024. Studies were eligible if they included patients with SLE (population), reported aPL status (exposure), and DAH (outcome). We pooled the estimates as odds ratio (OR) using fixed-effect models. We examined the association between aPL and DAH, as well as associations based on aPL subtypes or concomitant APS. Results Out of 454 screened studies, nine were included in meta-analysis, encompassing 7746 patients with SLE, of whom 2016 (26.0%) were aPL-positive and 163 (2.1%) had DAH. Patients with SLE and positive aPL (any) were more likely to develop DAH than aPL-negative patients (OR = 1.76, 95% CI 1.24–2.49; I2 = 0%). Patients with SLE and positive LA (OR = 1.76, 95% CI 1.06–2.93, I2 = 35%) or positive anticardiolipin IgG (OR = 1.62, 95% CI 1.13–2.34, I2 = 0%) had a higher likelihood of developing DAH compared with patients that were negative for these aPL. An APS diagnosis was associated with a 2.5-fold increased likelihood of DAH compared with subjects without APS (OR = 2.46, 95% CI 1.23–4.92, I2 = 0%). Positivity of anti-β2 glycoprotein I IgG was not significantly associated with DAH among patients with SLE (OR = 0.78, 95% CI 0.45–1.36, I2 = 0%). Conclusion In patients with SLE, aPL positivity increases the risk of DAH compared with aPL-negative patients, particularly in those positive for LA and anticardiolipin IgG.